Radius Health Announces Five Presentations on elacestrant (RAD1901) at the San Antonio Breast Cancer Symposium (SABCS)
December 04 2017 - 9:05AM
SABCS to include five abstracts from the development
program for elacestrant as a potential treatment of ER-positive
advanced breast cancer
Radius Health, Inc. (Nasdaq:RDUS), announced today that it will
present data from multiple clinical and pre-clinical studies of
elacestrant, an oral selective estrogen degrader, in ER-positive
breast cancer at the San Antonio Breast Cancer Symposium Meeting
December 5-9, 2017 at the Henry B. Gonzalez Convention Center in
San Antonio, Texas.
Details for the abstracts related to elacestrant are below:
Abstract Title: Elacestrant, a novel oral selective estrogen
receptor degrader (SERD), decreases tumoral 18F-FES uptake in a
phase 1 study of ER+, HER2 -, advanced breast cancer patients
Poster Session 1 (P1-10-04) Session Title: Treatment: New Drugs and
Treatment Strategies Session Date: Wednesday, 12/6/2017 Session
Time: 5:00 PM — 7:00 PM Location: Hall 1
Abstract Title: Elacestrant, oral selective estrogen receptor
degrader (SERD) in patients with ER positive (ER+)/HER2- advanced
breast cancer: Updated phase 1 efficacy, safety and pharmacodynamic
results Spotlight Session 5 (PD5-08) Session Title: Endocrine
Therapy: SERDS for metastatic ER+ breast cancer Session Date:
Thursday, 12/7/2017 Session Time: 5:00 PM — 7:00 PM Location:
Ballroom 1&2 - 3rd Level
Abstract Title: New oral SERD elacestrant (RAD1901) shows
efficacy in breast cancer models harbouring ESR1 mutations and
enhances the antiproliferative activity of mTORC1 and CDK4/6
inhibitors Poster Session 4 (P4-04-09) Session Title: Tumor Cell
and Molecular Biology: Endocrine Therapy and Resistance Session
Date: Friday, 12/8/2017 Session Time: 7:00 AM — 9:00 AM Location:
Hall 1
Abstract Title: Anti-tumor activity of elacestrant (RAD1901) in
combination with alpelisib (BYL-719) in patient-derived xenograft
models of ER+ breast cancer Poster Session 4 (P4-04-14) Session
Title: Tumor Cell and Molecular Biology: Endocrine Therapy and
Resistance Session Date: 12/8/2017 Session Time: 7:00 AM — 9:00 AM
Location: Hall 1
Abstract Title: Elacestrant (RAD1901) demonstrates anti-tumor
activity in a fulvestrant-resistant PDX model Poster Session 4
(P4-04-17) Session Title: Tumor Cell and Molecular Biology:
Endocrine Therapy and Resistance Session Date: 12/8/2017 Session
Time: 7:00 AM — 9:00 AM Location: Hall 1
Abstracts for the posters can be found on the SABCS website at
http://www.abstracts2view.com/sabcs/
Webcast Information
Radius will host an investor meeting and webcast on Thursday,
December 7th to highlight the elacestrant data presented at SABCS
and provide a company update at 8:00 p.m. CT / 9:00 p.m. ET.
The live webcast titled “Oncology Program Update from San
Antonio Breast Cancer Symposium – 2017” will be available at
https://edge.media-server.com/m6/p/ycgfk3pd or by visiting the
Investors section of Radius' website at
http://ir.radiuspharm.com/events.cfm.
A replay of the webcast will be archived on Radius' website for
30 days following the presentation.
About Elacestrant (RAD1901)Elacestrant is a
selective estrogen receptor degrader (SERD), which is being
evaluated for potential use as a once daily oral treatment for
hormone-receptor positive breast cancer. Elacestrant is currently
being investigated for potential use in women with advanced
estrogen receptor positive, HER2 negative, breast cancer, the most
common form of the disease. Studies completed to date indicate that
the compound has the potential for use as a single agent or in
combination with other therapies for the treatment of breast
cancer.
Additional information on the clinical trial program of
elacestrant (RAD1901) is available
on www.clinicaltrials.gov.
About Radius
Radius is a science-driven fully integrated biopharmaceutical
company that is committed to developing and commercializing
innovative therapeutics in the areas of osteoporosis, oncology and
endocrine diseases. Radius' lead product, TYMLOS (abaloparatide)
injection, was approved by the U.S. Food and Drug Administration
for the treatment of postmenopausal women with osteoporosis at high
risk for fracture. Radius' Marketing Authorisation Application
(MAA) for abaloparatide-SC for the treatment of postmenopausal
women with osteoporosis is under regulatory review in Europe. The
Radius clinical pipeline includes an investigational abaloparatide
transdermal patch for potential use in osteoporosis; the
investigational drug elacestrant (RAD1901) for potential use in
hormone-receptor positive breast cancer, and vasomotor symptoms in
postmenopausal women; and the investigational drug RAD140, a
non-steroidal, selective androgen receptor modulator (SARM) under
investigation for potential use in hormone-receptor positive breast
cancer. For more information, please visit www.radiuspharm.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do
not relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding the progress of abaloparatide-SC in the regulatory
process with the EMA, the progress in the development of our
product candidates, including abaloparatide-TD, elacestrant
(RAD1901) and RAD140, and the potential clinical uses and
therapeutic and other benefits of our product candidates, including
abaloparatide-TD, elacestrant and RAD140.
These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to, the
following: we expect to need to raise additional funding, which may
not be available; risks related to raising additional capital; our
limited operating history; quarterly fluctuation in our financial
results; our dependence on the success of TYMLOS, and our inability
to ensure that TYMLOS will obtain regulatory approval outside the
U.S. or be successfully commercialized in any market in which it is
approved, including as a result of risk related to coverage,
pricing and reimbursement; risks related to competitive products
and any collaboration agreements failing to be successful; risks
related to clinical trials, including our reliance on third parties
to conduct key portions of our clinical trials and uncertainty that
results will support our product candidate claims; the risk that
adverse side effects will be identified during the development of
our product candidates or during commercialization, if approved;
risks related to manufacturing, supply and distribution; and the
risk of litigation or other challenges regarding our intellectual
property rights. These and other important risks and uncertainties
discussed in our filings with the Securities and Exchange
Commission, or SEC, including under the caption "Risk Factors" in
our Quarterly Report on Form 10-Q for the period ending June 30,
2017 and subsequent filings with the SEC, could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any
such forward-looking statements represent management's estimates as
of the date of this press release. While we may elect to
update such forward-looking statements at some point in the future,
we disclaim any obligation to do so, even if subsequent events
cause our views to change. These forward-looking statements
should not be relied upon as representing our views as of any date
subsequent to the date of this press release.
Investor & Media Relations Contact:Alex
FudukidisEmail: alex.fudukidis@russopartnersllc.comPhone:
646-942-5632
Radius Recycling (NASDAQ:RDUS)
Historical Stock Chart
From Apr 2024 to May 2024
Radius Recycling (NASDAQ:RDUS)
Historical Stock Chart
From May 2023 to May 2024